Mismatched unrelated cord blood transplantation in a patient with T-cell prolymphocytic leukemia Leukemia (2005) T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive postthymic malignancy with a median survival of 7.5 months. [1] [2] [3] Conventional chemotherapies such as deoxycoformycin may offer transient responses, but their efficacy is limited, [1] [2] [3] [4] [5] [6] and there is currently no approved standard treatment for T-PLL. Here, we report the first patient with T-PLL who was successfully treated with unrelated cord blood (UCB) transplantation as salvage therapy after conventional chemotherapies failed.
In December 2003, a 52-year-old male presented with dyspnea on effort and dry cough. Physical examination revealed massive splenomegaly, facial edema and scattered, purplish, papular skin lesions on his extremities. His blood test showed a white blood cell (WBC) count of 76 Â 10 9 /l with 86% of abnormal lymphocytes, a hemoglobin level of 12.5 g/dl and a platelet count of 80 Â 10 9 /l. The lymphocytes were of small to medium size and had a folded nuclear outline, a single nucleolus and a deep basophilic cytoplasm. Flow cytometric analysis of peripheral blood lymphocytes revealed a postthymic T-cell phenotype (CD2 þ , CD3 þ , CD4 þ , CD5 þ , CD7 þ , CD8 þ ) with no B cell or myeloid antigens. Cytogenetic analysis revealed normal karyotype. The serological study for human Tlymphotropic virus 1 was negative. Bone marrow aspirate and pleural effusion aspirate showed massive infiltration of T prolymphocytes. Using peripheral blood samples, Southern blot analysis revealed a rearranged band in the T-cell receptor (TCR)-b chain gene. The diagnosis of T-PLL was made. The patient was treated sequentially with two regimens of combination chemotherapy (FND, fludarabine, mitoxantrone, dexamethasone; CHOP, cyclophosphamide, adriamycin, vincristine, prednisolone), and 2 0 -deoxycoformycin (DCF, 4 mg/m 2 weekly for four doses); however, these treatments did not result in complete remission. Since the disease could not be controlled by these treatments and was rapidly progressing, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was suggested. Since he had no human leukocyte antigen (HLA)-identical siblings and since coordinating an unrelated bone marrow transplantation would take a large amount of time, we proposed to perform a UCB transplantation. We made preparation for UCB transplantation using an unrelated banked UCB unit from the Placental Blood Bank at Tokyo through the Japan Cord Blood Bank Network. 7 The patient's weight was 58 kg and we could find suitable UCB as shown in Table 1 . The patient and donor cord blood were serologically and genotypically mismatched, that is, one-antigen mismatched in the graft-vs-host direction and two- antigen mismatched in the host-vs-graft direction. Before the beginning of conditioning regimen, the percentage of leukemic cells was 59% of WBC and 49% of BM nuclear cells, respectively. Myeloablative conditioning consisted of cyclophosphamide 60 mg/kg/day for 2 days and total body irradiation (TBI) at a dose of 1200 cGy in six fractions. In March 2004, the patient received UCB (nucleated cell dose 2.95 Â 10 7 /kg, CD34-positive cell dose 1.18 Â 10 5 /kg), and underwent standard infection prophylaxis. Graft-vs-host disease (GVHD) prophylaxis consisted of 3 mg/kg/day cyclosporine (continuous intravenous infusion, dosed to deliver a target concentration of 150-250 ng/ml) and methotrexate (day þ 1, 10 mg/m 2 ; days þ 3 and þ 6, 7 mg/m 2 ). Granulocyte-colony stimulating factor was administered from day þ 5 until engraftment. He engrafted with a neutrophil count of greater than 0.5 Â 10 9 /l on day þ 35 post-transplant. Polymerase chain reaction-based DNA microsatellite polymorphism analysis revealed complete donor chimerism on day þ 60. Additionally, Southern blot analysis demonstrated no rearranged band in the TCR-b chain gene. The patient achieved red cell transfusion independence and platelet transfusion independence on day þ 65 post-transplant. The post-transplant course was complicated by engraftment syndrome with grade I skin GVHD, which resolved with lowdose prednisolone (0.5 mg/kg per day). Other complications included veno-occlusive disease, episodes of neutropenic fever and reactivation of herpes simplex virus, but he was managed successfully with supportive measures. His subsequent posttransplant course was uneventful. Flow cytometric analysis of peripheral blood samples showed that 3% of the lymphocytes obtained on day þ 30 and 0.6% of the lymphocytes obtained on day þ 60 were CD4 þ CD8 þ residual tumor cells. At 9 months after allo-HSCT, the patient shows no signs of relapse with complete donor chimerism and negative TCR rearrangement, or no signs of chronic GVHD and is in good clinical condition.
T-PLL is a rare leukemia characterized by high white blood cell count, splenomegaly, lymphadenopathy, skin infiltration and a very aggressive clinical course. The median age at presentation is 69 years. 8 Flow cytometric analysis of lymphocytes shows a post-thymic phenotype, and 21% of cases have coexpression of CD4 and CD8 like our case. 1 Some patients with T-PLL respond to alkylating agent-containing regimen such as the CHOP regimen, in which one-third of patients achieve short-lived responses, or DCF with a 40-50% overall response. 1, 4 The purine analog, 2-chlorodeoxyadenosine, has been reported to be active against T-PLL, but its efficacy is also limited. 5, 6 Campath-1H is a monoclonal agent with promising results; 2,3 however, although T-PLL may initially respond to Campath-1H, disease progression subsequently occurs. Thus, this disease is considered to be essentially incurable. Therefore, we considered that allo-HSCT was the only treatment that can potentially cure the disease. Recently, the use of UCB has emerged as an appealing alternative stem cell source for patients who do not have HLA-identical donors and those who urgently require treatment. Prompt availability of donor cells is a key part of the management of this rapidly progressing disease. Therefore, we performed UCB transplantation instead of bone marrow transplantation from an unrelated adult donor. To our knowledge, this is the first report of T-PLL that was successfully treated by UCB transplantation. The potential of allo-HSCT to cure T-PLL was demonstrated in previous reports (Table 2) . 2, [9] [10] [11] Among the seven reported T-PLL cases who underwent allo-HSCT, one had a relapse and died of the disease and a second patient died of transplant-related complications, while five patients were alive and in complete remission. This may suggest that allo-HSCT could be an effective strategy for the treatment of T-PLL. The use of UCB as a stem cell source can broaden the number of eligible patients who would benefit from allo-HSCT. Unlike unrelated adult-derived hematopoietic stem cells, UCB products are readily available for most patients because there is reduced stringency for product selection based on HLA type, and the UCB HLA typing is usually done at the time of storage. 12 It is therefore feasible to perform transplantation in patients who urgently require treatment before they are exposed to excessive amounts of chemotherapeutic agents. While a lower incidence of GVHD is a potential benefit of UCB transplantation, there is concern that UCB may not be able to induce a sufficient graftvs-leukemia (GVL) effect, resulting in increased relapse rates and limiting its practical utility. It is impossible to determine the relative contributions of chemoradiotherapy and the GVL effect in the eradication of our patient's leukemia; however, T-PLL cells remained after the myeloablative conditioning regimen and slowly disappeared after UCB transplantation. Thus, our case suggests that UCB has the potential to generate a GVL effect. In summary, UCB transplantation could be offered to adult patients with T-PLL who urgently require allo-HSCT but do not have HLA-matched siblings. This alternative stem cell source enables more patients with T-PLL to undergo allo-HSCT. The Second Department of Internal Medicine, Kurume Univesity School of Medicine, Kurume, Japan T-PLL, T-prolymphocytic leukemia; HSCT, hematopoietic stem cell transplantation; CR, complete remission; PR, partial remission; NR, no remission; CY, cyclophosphamide; TBI, total body irradiation; FDR, fludarabine; TRM, transplantation-related mortality; UCB, unrelated cord blood.
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